美国质体DNA 製造市场规模、份额和趋势分析报告：按疾病、等级、应用、开发阶段和细分市场预测，2025 年至 2033 年

美国质体DNA製造市场摘要

美国质体DNA 製造市场预计在 2024 年价值 8.03 亿美元，预计到 2033 年将达到 50.38 亿美元，2025 年至 2033 年的复合年增长率为 23.06%。这一扩张是由对基因疗法、DNA 疫苗和其他使用高品质质体DNA 作为其组成部分的先进生技药品的需求不断增长所推动的。

预计在预测期内，对生物技术研究的持续投资和支持性法律规范将进一步推动市场发展。

遗传疾病和癌症盛行率上升

遗传疾病和癌症的发生率不断上升是推动美国质体DNA製造业成长的主要因素。基因研究的进展揭示了基因突变和异常在各种疾病中的作用，从而促进了旨在从根本上治癒这些疾病的基因疗法的发展。同样，癌症治疗也正朝着个人化和标靶治疗的方向发展，其中许多疗法都依赖质体DNA作为载体来递送治疗基因或免疫调节剂。随着诊断技术的进步和人口老化，越来越多的患者被确定为这些创新治疗方法的候选人，从而扩大了对质体DNA的需求。

此外，基因疗法和癌症治疗的复杂性和个人化特性要求质体DNA的生产过程高度专业化且可扩展。生物技术公司和研究机构正在大力投资开发灵活的生产平台，以满足临床和商业应用的严格品质标准和数量要求。精准医疗和个人化治疗日益受到关注，推动着市场持续扩张，而质体DNA在先进疗法的研发中发挥关键作用。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

• 市场体系展望
  • 母市场展望
  • 相关/辅助市场展望
• 市场趋势与展望
• 市场动态
  • 选择基因治疗的患者数量不断增加
  • 强大的基因治疗管道
  • 市场竞争激烈，市场参与企业策略多元
  • 各种医疗治疗对质体DNA 的需求不断增加
• 市场限制因素分析
  • 与基因治疗相关的监管、科学和伦理挑战
• 商业环境分析
  • PESTEL分析
  • 波特五力分析

第四章 等级商业分析

• 细分仪表板
• 美国质体DNA製造市场的波动
• 美国质体DNA 製造市场规模及趋势分析（依等级）（2021-2033）
• 研发级
  • 研发级市场，2021-2033
  • 病毒载体开发
  • mRNA发育
  • 抗体开发
  • DNA疫苗开发
  • 其他的
• GMP级
  • GMP级市场，2021-2033年

第五章：开发阶段的商业分析

• 细分仪表板
• 美国质体DNA製造市场的波动
• 美国质体DNA 製造市场规模及发展阶段趋势分析（2021-2033 年）
• 临床前治疗
• 临床治疗
• 非处方药

第六章：应用业务分析

• 细分仪表板
• 美国质体DNA製造市场的波动
• 美国质体DNA 製造市场规模与趋势分析（按应用）（2021-2033）
• DNA疫苗
• 细胞和基因治疗
• 免疫疗法
• 其他的

第七章疾病业务分析

• 细分仪表板
• 美国质体DNA製造市场的波动
• 美国质体DNA 製造市场规模与趋势分析（按疾病，2021-2033 年）
• 感染疾病
• 癌症
• 遗传性疾病
• 其他的

第八章 竞争态势

• 参与企业
• 2024年企业市场分析
• 参与企业概况
  • Charles River Laboratories
  • Danaher（Aldevron）
  • VGXI, Inc.
  • Kaneka Corp.
  • Lonza
  • Nature Technology
  • Cell and Gene Therapy Catapult
  • Eurofins Genomics
  • Luminous BioSciences, LLC
  • Akron Biotech

U.S. Plasmid DNA Manufacturing Market Summary

The U.S. plasmid DNA manufacturing market size was estimated at USD 803.0 million in 2024 and is projected to reach USD 5,038.0 million by 2033, growing at a CAGR of 23.06% from 2025 to 2033. This expansion is driven by increasing demand for gene therapies, DNA vaccines, and other advanced biologics that rely on high-quality plasmid DNA as a foundational component.

Continued investment in biotechnology research and supportive regulatory frameworks are expected to propel market development further over the forecast period.

Rising Prevalence of Genetic Disorders and Cancer

The rising prevalence of genetic disorders and cancer is a major factor driving growth in the U.S. plasmid DNA manufacturing industry. Advances in genetic research have highlighted the role of gene mutations and abnormalities in various diseases, leading to increased development of gene therapies aimed at treating these conditions at their source. Similarly, cancer treatment is increasingly shifting toward personalized and targeted therapies, many of which depend on plasmid DNA as a vector to deliver therapeutic genes or immune modulators. As diagnostic technologies improve and the population ages, more patients are identified as candidates for these innovative therapies, expanding the demand for plasmid DNA.

Moreover, the complex and individualized nature of genetic and cancer therapies requires highly specialized and scalable plasmid DNA manufacturing processes. Biotech companies and research institutions invest heavily in developing flexible production platforms that meet the' rigorous quality standards and volume demands of clinical and commercial applications. This increased focus on precision medicine and tailored treatments further solidifies plasmid DNA's role as a critical component in the evolving landscape of advanced therapeutics, driving sustained market expansion.

U.S. Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. plasmid DNA manufacturing market report based on grade, development phase, application, and disease:

• Grade Outlook (Revenue, USD Million, 2021 - 2033)
• R&D Grade
  • Viral Vector Development
  • AAV
  • Lentivirus
  • Adenovirus
  • Retrovirus
  • Others
  • mRNA Development
  • Antibody Development
  • DNA Vaccine Development
  • Others
• GMP Grade
• Development Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Clinical Therapeutics
• Clinical Therapeutics
• Marketed Therapeutics
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• DNA Vaccines
• Cell & Gene Therapy
• Immunotherapy
• Others
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Infectious Disease
• Cancer
• Genetic Disorder
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Grade
  • 1.2.2. Development Phase
  • 1.2.3. Application
  • 1.2.4. Disease
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
  • 1.9.1. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Increasing number of patients opting for gene therapy
  • 3.3.2. Robust pipeline for gene therapies
  • 3.3.3. Highly competitive market and various strategies undertaken by market players
  • 3.3.4. Increasing demand for plasmid DNA in various medical therapies
• 3.4. Market Restraint Analysis
  • 3.4.1. Regulatory, scientific, and ethical challenges associated with gene therapy
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Grade Business Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
• 4.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2021 to 2033 (USD Million)
• 4.4. R&D Grade
  • 4.4.1. R&D Grade Market, 2021 - 2033 (USD Million)
  • 4.4.2. Viral Vector Development
    • 4.4.2.1. Viral Vector Development Market, 2021 - 2033 (USD Million)
    • 4.4.2.2. AAV
      • 4.4.2.2.1. AAV Market, 2021 - 2033 (USD Million)
    • 4.4.2.3. Lentivirus
      • 4.4.2.3.1. Lentivirus Market, 2021 - 2033 (USD Million)
    • 4.4.2.4. Adenovirus
      • 4.4.2.4.1. Adenovirus Market, 2021 - 2033 (USD Million)
    • 4.4.2.5. Retrovirus
      • 4.4.2.5.1. Retrovirus Market, 2021 - 2033 (USD Million)
    • 4.4.2.6. Others
      • 4.4.2.6.1. Others Market, 2021 - 2033 (USD Million)
  • 4.4.3. mRNA Development
    • 4.4.3.1. mRNA Development Market, 2021 - 2033 (USD Million)
  • 4.4.4. Antibody Development
    • 4.4.4.1. Antibody Development Market, 2021 - 2033 (USD Million)
  • 4.4.5. DNA Vaccine Development
    • 4.4.5.1. DNA Vaccine Development Market, 2021 - 2033 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market, 2021 - 2033 (USD Million)
• 4.5. GMP Grade
  • 4.5.1. GMP Grade Market, 2021 - 2033 (USD Million)

Chapter 5. Development Phase Business Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
• 5.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2021 to 2033 (USD Million)
• 5.4. Pre-Clinical Therapeutics
  • 5.4.1. Pre-Clinical Therapeutics Market, 2021 - 2033 (USD Million)
• 5.5. Clinical Therapeutics
  • 5.5.1. Clinical Therapeutics Market, 2021 - 2033 (USD Million)
• 5.6. Marketed Therapeutics
  • 5.6.1. Marketed Therapeutics Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
• 6.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. DNA Vaccines
  • 6.4.1. DNA Vaccines Market, 2021 - 2033 (USD Million)
• 6.5. Cell & Gene Therapy
  • 6.5.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Million)
• 6.6. Immunotherapy
  • 6.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Disease Business Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
• 7.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
• 7.4. Infectious Disease
  • 7.4.1. Infectious Disease Market, 2021 - 2033 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer Market, 2021 - 2033 (USD Million)
• 7.6. Genetic Disorder
  • 7.6.1. Genetic Disorder Market, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Participant's Overview
  • 8.3.1. Charles River Laboratories
    • 8.3.1.1. Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Danaher (Aldevron)
    • 8.3.2.1. Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. VGXI, Inc.
    • 8.3.3.1. Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Kaneka Corp.
    • 8.3.4.1. Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Lonza
    • 8.3.5.1. Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Nature Technology
    • 8.3.6.1. Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Cell and Gene Therapy Catapult
    • 8.3.7.1. Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Eurofins Genomics
    • 8.3.8.1. Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Luminous BioSciences, LLC
    • 8.3.9.1. Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Akron Biotech
    • 8.3.10.1. Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product Benchmarking
    • 8.3.10.4. Strategic Initiatives

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 List Of Abbreviations
• Table 3 U.S. Plasmid DNA Manufacturing Market by Grade, 2021 - 2033 (USD Million)
• Table 4 U.S. Plasmid DNA Manufacturing Market by Development Phase, 2021 - 2033 (USD Million)
• Table 5 U.S. Plasmid DNA Manufacturing Market by Application, 2021 - 2033 (USD Million)
• Table 6 U.S. Plasmid DNA Manufacturing Market by Disease, 2021 - 2033 (USD Million)
• Table 7 Participant's Overview

List of Figures

• Fig. 1 U.S. plasmid DNA manufacturing market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Market outlook
• Fig. 8 Segment snapshot
• Fig. 9 Competitive landscape snapshot
• Fig. 10 Parent market outlook
• Fig. 11 U.S. plasmid DNA manufacturing market driver analysis
• Fig. 12 U.S. plasmid DNA manufacturing market restraint analysis
• Fig. 13 U.S. plasmid DNA manufacturing market: Porter's analysis
• Fig. 14 U.S. plasmid DNA manufacturing market: PESTEL analysis
• Fig. 15 U.S. plasmid DNA manufacturing market: Grade outlook and key takeaways
• Fig. 16 U.S. plasmid DNA manufacturing market: Grade movement analysis
• Fig. 17 U.S. R&D grade market, 2021 - 2033 (USD Million)
• Fig. 18 U.S. viral vector development market, 2021 - 2033 (USD Million)
• Fig. 19 U.S. mRNA development market, 2021 - 2033 (USD Million)
• Fig. 20 U.S. antibody development market, 2021 - 2033 (USD Million)
• Fig. 21 U.S. DNA vaccine development market, 2021 - 2033 (USD Million)
• Fig. 22 U.S. others market, 2021 - 2033 (USD Million)
• Fig. 23 U.S. AAV market, 2021 - 2033 (USD Million)
• Fig. 24 U.S. lentivirus market, 2021 - 2033 (USD Million)
• Fig. 25 U.S. adenovirus market, 2021 - 2033 (USD Million)
• Fig. 26 U.S. retrovirus market, 2021 - 2033 (USD Million)
• Fig. 27 U.S. GMP grade market, 2021 - 2033 (USD Million)
• Fig. 28 U.S. others market, 2021 - 2033 (USD Million)
• Fig. 29 U.S. plasmid DNA manufacturing market: Development phase outlook and key takeaways
• Fig. 30 U.S. plasmid DNA manufacturing market: Development phase movement analysis
• Fig. 31 U.S. pre-clinical therapeutics market, 2021 - 2033 (USD Million)
• Fig. 32 U.S. clinical therapeutics market, 2021 - 2033 (USD Million)
• Fig. 33 U.S. marketed therapeutics market, 2021 - 2033 (USD Million)
• Fig. 34 U.S. plasmid DNA manufacturing market: Application outlook and key takeaways
• Fig. 35 U.S. plasmid DNA manufacturing market: Application movement analysis
• Fig. 36 U.S. DNA vaccines market, 2021 - 2033 (USD Million)
• Fig. 37 U.S. cell & gene therapy market, 2021 - 2033 (USD Million)
• Fig. 38 U.S. immunotherapy market, 2021 - 2033 (USD Million)
• Fig. 39 U.S. others market, 2021 - 2033 (USD Million)
• Fig. 40 U.S. plasmid DNA manufacturing market: Disease outlook and key takeaways
• Fig. 41 U.S. plasmid DNA manufacturing market: Disease movement analysis
• Fig. 42 U.S. infectious disease market, 2021 - 2033 (USD Million)
• Fig. 43 U.S. cancer market, 2021 - 2033 (USD Million)
• Fig. 44 U.S. genetic disorder market, 2021 - 2033 (USD Million)
• Fig. 45 U.S. others market, 2021 - 2033 (USD Million)